Mirus was founded in 1995 to address the limitations and risks of viral gene transfer. We developed the first pDNA transfection method that combined high efficiency with low cellular toxicity, and since that time, we’ve focused on applying intentional design to …

Mirus Bio LLC (formerly Mirus Bio Corporation), develops and manufactures transfection reagents, electroporation solutions and related products for life science research.

Mar 26, 2024 · Since its founding in 1995, Mirus Bio has been meeting industry and customer needs through innovation, collaboration and partnerships.

May 22, 2024 · Merck, a leading science and technology company, has signed a definitive agreement to acquire life science company Mirus Bio for US$ 600 million (around € 550 million). Based in Madison, Wisconsin, USA, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

Mirus Bio Global Distributors; Support; Our Technology. Transfection is a Complex Process. Transfecting cells is a critical step in producing viral vectors for cell and gene therapies, manufacturing recombinant proteins and monoclonal antibodies for immunotherapies, editing genes through CRISPR, and applying a range of other applications such ...

Aug 1, 2024 · Mirus Bio’s leading GMP transfection reagents complement company’s upstream bioprocessing portfolio; Combined portfolio meets customer needs as demand for novel modalities grows

May 22, 2024 · Mirus Bio’s transfection reagents strengthen Merck’s upstream portfolio; Acquisition will advance Merck’s ambition to provide a fully integrated and comprehensive solution for viral vector manufacturing; Reinforces Merck’s continued commitment to shaping the future of gene therapies and other novel modalities

Aug 1, 2024 · The addition of Mirus Bio’s leading transfection reagents strengthens MilliporeSigma's upstream portfolio and allows for an integrated viral vector manufacturing offering.

Aug 2, 2024 · Germany-based Merck KGaA has concluded the acquisition of Mirus Bio for €500m ($600m), enhancing its viral vector bioprocessing capabilities. The companies entered a definitive agreement in May 2024 under which Merck’s Life Science business in the US and Canada, MilliporeSigma, would acquire Mirus Bio.

A high efficiency electroporation solution compatible with most conventional electroporation devices including Lonza-Amaxa®, Bio-Rad® or Harvard BTX®. Delivers CRISPR/Cas9 components in the following formats: DNA – Deliver plasmid DNA expressing Cas9 or guide RNA; mRNA – Deliver messenger RNA expressing Cas9